This study is testing whether a soy isoflavone supplement (Novasoy) can help infants at high risk for asthma. We're looking for babies between 2 and 12 months old who have a specific genetic variation that makes them produce more of a protein called plasminogen activator inhibitor-1 (PAI-1), which can cause inflammation. Participants will receive either the soy isoflavone supplement or a matching placebo (an inactive substance) twice daily for 7 months. The main goal is to see if the soy isoflavones can reduce the number of infants with a specific type of asthma (T2 high endotype) and also decrease wheezing episodes. The study is currently unclear on its recruitment status.

Study design

This is a randomized, quadruple-masked, placebo-controlled study involving 65 infants. Participants will be assigned by chance to receive either the soy isoflavone supplement or a placebo, and neither you nor the study team will know which one you are receiving.

What's involved

Participants will take a supplement twice daily for 7 months. There will be 3 required in-person visits and 6 virtual visits in the first year, plus additional in-person visits if your child has a viral illness.

Compensation

Not stated in the trial record.

Follow-up

After the 7-month treatment period, there will be a 1-year observation period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.